N/A Completed N=12 Randomized Quadruple-blind Prevention

Colonic Propionate, Appetite, and Weight Loss

Healthy Obesity, Metabolically · Appetite Regulation

Source: ClinicalTrials.gov NCT03322514 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2019

Primary outcomePrimary: Change in Weight Loss Compared to Baseline — -2.6; -3 kg — p=0.8

Summary

The current protocol aims to investigate the impact of the propionate ester in conjugation with restricted diet on appetite and weight loss.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in Weight Loss Compared to Baseline	-2.6; -3	0.8
SECONDARY Glucose Blood Level Baseline to 12 Weeks	4.9; 4.4; 5.1; 4.8	0.8
SECONDARY Insulin Level in Serum	50.4; 48.9; 41.0; 46.0	0.9

Eligibility Criteria

Inclusion Criteria

overweight or obese ((BMI) of 25-35 kg/m2)
healthy
aged between 18 and 65 years

Exclusion Criteria

Weight change of ≥ 3kg in the preceding 2 months
Undergone any weight loss surgery or gastric procedures to promote weight loss
Current smokers
Substance abuse
Excess alcohol intake
Pregnancy
Diabetes
Cardiovascular disease
Cancer
Gastrointestinal disease e.g. inflammatory bowel disease or irritable bowel syndrome
Kidney disease
Liver disease
Pancreatitis
Use of medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including: anti-inflammatory drugs or steroids, antibiotics, androgens, phenytoin, erythromycin or thyroid hormones.

Any participants with the above conditions would already have an altered pattern of hormones and inflammatory molecules because of their disease process and would therefore give us confounding or misleading results.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03322514). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.